Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | MASP2 | O00187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13294155 | 1.00 | SCN10A (0.42) | SCN10ASCN5ANLNSSTR1MASP2 | |
| SCHEMBL20221259 | 0.92 | CYP2A6 (0.43) | SCN10ASCN5ANLN | |
| SCHEMBL15105893 | 0.91 | SCN10A (0.39) | SCN10ASCN5ANLN | |
| SCHEMBL19324126 | 0.90 | TRPV1 (0.42) | SCN10ASCN5ANLNMASP2 | |
| SCHEMBL18480460 | 0.90 | MASP2 (0.51) | SSTR1MASP2 | |
| Hydrochloric Acid SCHEMBL18438825 | 0.88 | MASP2 (0.50) | SSTR1MASP2 | |
| SCHEMBL19388182 | 0.88 | SCN10A (0.53) | SCN10ASCN5ANLNSSTR1 | |
| SCHEMBL15116822 | 0.85 | NLN (0.48) | SCN10ASCN5ANLN | |
| SCHEMBL20054551 | 0.85 | NLN (0.48) | SCN10ASCN5ANLN | |
| SCHEMBL19388724 | 0.85 | NLN (0.48) | SCN10ASCN5ANLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-9326973-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013106520-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-2250163-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-28 | — | — | EP | disclosed |
| US-7745636-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745636-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2009102318-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183269-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885SCN5A 3899/4885NLN 4268/4885 |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | SCN10A 4625/4885SCN5A 4586/4885NLN 3435/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885SCN5A 3899/4885NLN 4268/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885SCN5A 3899/4885NLN 4268/4885 |
| US-20150297568-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SCN10A 4191/4885SCN5A 3899/4885NLN 4268/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | SCN10A 4318/4885SCN5A 4146/4885NLN 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.